Company and Stock Identity

How Recursion Connects to the Public Market

Company structure
Public company
Market access
Direct listing: Nasdaq: RXRX.
Stock name
Recursion Pharmaceuticals, Inc.
Ticker and exchange
Nasdaq: RXRX
Research focus
Separate platform milestones, partner payments, and owned clinical programs. Model scale is not a clinical endpoint, so follow program stage, cash use, and partner decisions.

Recursion is a publicly listed clinical-stage biotechnology company.

Dated Market Snapshot

Oct 26, 2026

Last price
$3.80
Change
+2.70%
Previous close
$3.70
52-week high / low
$6.5/$2.77
Market cap
2,268,152,246

Automated from Nasdaq. Check the exchange or investor-relations page for the current price.

Open the public company market data feed for the full directory, ownership relationships, stock identifiers, and dated snapshots.

First-Hand Company News

Latest Developments

... Recursion Investor Relations ... Investor relations

Recursion reports second-quarter results and a Genentech target decision

Recursion reported that Genentech advanced the collaboration’s first neuroscience target into a joint early discovery program alongside its quarterly business update.

Why it matters: A partner choosing to advance a target says more than another AI platform announcement. Genentech is committing joint discovery work to something found in the collaboration. It is still early, but it is the kind of step investors can track from computational discovery toward a possible drug program.

See company developments across the healthcare AI market.

Careers and Qualifications

What to Know Before Applying

Work areas: Computational biology, machine learning, automation, drug discovery, clinical development, engineering, and business development.

Qualification signal: Scientific and technical roles often require advanced quantitative or life-sciences depth. Public filings help applicants understand which programs and capabilities the company is funding now.

Check current roles at Recursion. A careers page is the source of record for openings. This profile does not claim a role is open unless the company lists it now.

Related Healthcare AI Roles

Training to Compare

Buyer Snapshot

Best-fit buyer
Pharmaceutical R&D, biotechnology leadership, translational science, business development, and investors
Primary use case
Identify targets, design molecules, prioritize experiments, and connect biomedical data to research decisions
Typical deployment
Ranges from software and data partnerships to platform collaborations and internally owned drug pipelines

Evidence questions

  • Which results are prospective, reproduced, and tied to a clinical or experimental endpoint?
  • How many programs are AI-originated, AI-assisted, partnered, or internally owned?
  • What has advanced beyond target identification and preclinical reporting?

Regulatory and workflow questions

  • Which entity owns development, validation, and regulatory responsibility for each program?
  • How are model-generated hypotheses reviewed before experimental or clinical use?
  • What claims are about research productivity versus a regulated product?

Data and contract questions

  • Who owns generated molecules, targets, models, and derived data?
  • Which proprietary datasets create defensibility and which are licensed?
  • Can a partner reproduce outputs and export project data after the collaboration?

Evidence and Regulation

FDA Clearances on Record

No clearance is linked in this directory. That is not automatically a mark against the company. Some products support the people doing the work instead of reading a patient image or signal themselves.

First-Hand Sources